

Corporate Presentation

November 2021



Safe Harbor Statement

This presentation includes forward-looking statements about, among other things, Verastem Oncology's programs and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Verastem Oncology's product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of our product candidates, including defactinib in combination with VS-6766; the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis or result in unmanageable safety profiles as compared to their levels of efficacy; or our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates.

Additional information regarding these factors can be found in Verastem Oncology's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in any subsequent filings with the SEC, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors that May Affect Future Results," as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.verastem.com.

The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.



Verastem Oncology Well Positioned to Capitalize on Growth Opportunities

New lead clinical program has best-in-class potential VS-6766 (RAF/MEKi) and defactinib (FAKi) are clinically active against RAS mutant cancers

We are a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer Rapid development paths to market

Significant downstream market opportunity and blockbuster potential

Strong balance sheet

FDA Breakthrough Therapy Designation in LGSOC; Supported by clinical results achieved in low-grade serous ovarian cancer (LGSOC), strong signal in KRAS G12V mutant NSCLC; registration-directed trials initiated in 4Q 2020

30% of all human cancers are driven by mutations in RAS; VS-6766 combinations potentially broadly applicable across a variety of tumor types.

Clinical collaborations with Amgen & Mirati evaluating the combinations of VS-6766 with sotorasib & adagrasib, respectively, in KRAS G12C mutant NSCLC supported by strong pre-clinical rationale

Monetization of COPIKTRA® (duvelisib) provides funding of current programs until at least 2024

Cash Balance of \$103.4 million, as of September 30, 2021

Debt reduced from approx. \$185M to \$0M (2019-2021)

Annual operating expense forecast of approximately \$55-60 million

Verastem Oncology Strategic Transformation



Q3 2020: Divested global rights to Copiktra to Secura Bio



Q4 2020: Initiated registration-directed ph. 2 study in LGSOC Initiated registration-directed ph. 2 study in NSCLC

QI 2021: LGSOC study updated to include KRAS wild type patients



Q2 2021: FDA Breakthrough Therapy Designation granted for VS-6766 + Defactinib in LGSOC



Q3 2021: Remaining outstanding debt retired VS-6766 + sotorasib Collaboration agreement with Amgen

Q4 2021: VS-6766 + adagrasib Collaboration agreement with Mirati



VS-6766 RAF/MEK Inhibitor Program Overview




VS-6766 is a differentiated, best-in-class asset potentially applicable across multiple patient populations

- Unique dual RAF/MEK targeting mechanism of action
- Best-in-class safety & tolerability profile relative to marketed MEK inhibitors, with potential for combinability with agents from multiple target classes
- Novel intermittent dosing schedule; convenient oral regimen
- Promising signals of clinical activity in various RAS-driven cancers, including in patients whose tumors previously progressed on other MEK inhibitors
- Preclinical anti-proliferative activity across multiple MAPK pathway alterations (e.g. KRAS, NRAS, BRAF, NF1 mt) and multiple solid tumor indications
- Strong preclinical combination data with other agents targeting RAS pathway and parallel pathways



High Priority Lead Indications with Multiple Growth Opportunities



- NRAS mt^{1,2}
- CRAF mt/fusions²

² Supported by preclinical data

¹ Supported by clinical data

FRASTEM

Robust Pipeline Targeting the RAS Pathway and Multiple Growth Opportunities

VS-6766 + DEFACTINIB	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET
RAMP-201 ¹ KRAS mt/wt LGSOC			FDA	Breakthrough Therapy Designat	tion for VS-6766 + defactini
RAMP-202 ¹ KRAS mt G12V NSCLC					
FRAME study Advanced LGSOC			7		
FRAME study Advanced KRAS mt NSCLC			7		
FRAME study Advanced CRC			7		
FRAME study Advanced KRAS-G12V mt NSCLC			7		
FRAME study Advanced pancreatic cancer			7		
FRAME study Advanced KRAS mt endometrioid cancer			7		
Metastatic uveal melanoma					


VS-6766 + OTHER COMBINATIONS	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET
KRAS mt NSCLC VS-6766 + everolimus (mTORi)					
RAMP-203 KRAS mt NSCLC VS-6766 + sotorasib (G12Ci)		Clinical Collaboration	Initiated with AMGEN		
KRAS mt NSCLC VS-6766 + adagrasib (G12Ci)		Clinical Collaboration			

¹Registration-directed trial *Pre-clinical studies ongoing in multiple KRAS mutant tumors


RAMP 201 study = NCT04625270 RAMP 202 study = NCT04620330 RAMP 203 study = NCT05074810 FRAME study = NCT03875820




VS-6766 is a Unique Small Molecule RAF/MEK Inhibitor



- VS-6766 inhibits both MEK & RAF kinase activities
- MEK inhibitors paradoxically induce MEK phosphorylation (pMEK) by relieving ERK-dependent feedback inhibition of RAF
- By inhibiting RAF phosphorylation of MEK, VS-6766 has advantage of not inducing pMEK
- VS-6766 inhibits ERK signaling more completely; may confer enhanced therapeutic activity




VS-6766 inhibits cell proliferation across multiple MAPK pathway alterations and multiple solid tumor indications





Vertical Blockade: Establishing VS-6766 as the backbone of therapy for RAS pathway-driven tumors




Current Challenges

- Blocking any single target in the pathway is insufficient for maximum depth and duration of anti-tumor efficacy
 - e.g., SHP2i, KRAS-G12Ci, RAFi, MEKi, ERKi
- Vertical blockade concept is now well established
 - Necessary to block more than I target in the pathway
- Many of these agents (e.g., SHP2i, MEKi) have poor tolerability as monotherapy and in combination

Solutions offered by VS-6766

- Vertical blockade (RAF and MEK blockade) in a single drug
- Best-in-class tolerability with established twice weekly dosing regimen
 - Should enable tolerable combinations
- Compelling synergy data (preclinical) for VS-6766 combinations (e.g., with KRAS-GI2C inhibitors) supporting clinical combinations

Parallel Pathway Inhibition: Establishing VS-6766 as the backbone of therapy for RAS pathway-driven tumors



Current Challenges

- Blocking Ras pathway can be circumvented through parallel pathways
 - e.g., PI3K/AKT/mTOR, FAK, RhoA, YAP
- Combinations of MEKi + AKTi have shown poor tolerability

Solutions offered with VS-6766

- Good tolerability with twice weekly VS-6766 opens up intermittent dosing options for combinations
- Compelling preclinical synergy data with VS-6766 in combination with FAK inhibition and with AKT pathway inhibition (e.g., everolimus)
- RP2D established for VS-6766 + defactinib and for VS-6766 + mTORi (everolimus) with twice weekly regimen

VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Favorable Tolerability Profile with Novel Intermittent Dosing Regimen

Summary of Adverse Events Grade \geq 3 Occurring in \geq 5% of patients

	VS-6766 monotherapy Daily at MTD N=6 28-day cycle	RP2D VS-6766 monotherapy 4mg twice weekly N=26 28-day cycle	RP2D (VS-6766 3.2mg twice weekly + defactinib 200mg twice daily) N=38 21 days of 28-day cycle
Treatment Related Adverse Event	Grade ≥3	Grade ≥3	Grade ≥3
Rash	3 (50%)	5 (19%)	2 (5%)
CK elevation (Creatine phosphokinase)	I (17%)	2 (8%)	2 (5%)

Summary of FRAME Safety Profile

Most Adverse Events (AE) were Grade 1/2

Few patients have discontinued due to AEs in the study



Favorable Tolerability Profile at Recommended Phase 2 dose for VS-6766 plus defactinib combination regimen

Treatment Related Adverse Events Details* (≥10% patients in cohort 3.2mg 6766 and Def 200mg)	VS-6766 4mg Twice Weekly (4 wks of every 4 wks) ¹ n=22		VS-6766 3.2mg Twice Weekly Def 200mg BID (3 wks of every 4 wks) ² n=38	
	Grl/2	Gr3/4	Grl/2	Gr3/4
Rash	15	5	32	2
CK Elevation	13	2	19	2
AST Elevation	I		13	
Hyperbilirubinemia			14	L
Visual Disturbance	13		9	
ALT Elevation	2		5	
Diarrhoea	6	I	14	L
Fatigue	5	I	8	L
Oral Mucositis [^]	7	I	11	
Nausea	5		5	
Vomiting	2		4	
Peripheral Edema	9		10	
Paronychia	3		4	
Thrombocytopenia			6	
Pruritus	3	0	5	

Summary of FRAME Safety Profile

- Most Adverse Events (AE) were Grade 1/2
- Few patients have discontinued due to AEs in the study


RP2D

- VS-6766 3.2 mg oral twice wkly (3 wks of every 4 wks)
- Defactinib 200 mg oral BID (3 wks of every 4 wks)


*AEs were graded by NCI CTC v4; highest grade only recorded for each patient; AEs presented in ≥10% Patient (cohort 3.2mg 6766 and Def 200mg) data preliminary and subject to change; ^also includes glossitis/mouth ulcers



VS-6766 in Combination with Defactinib Shows Promising ORR with Durability in Refractory LGSOC with Expanded Number of Patients (n=24)



LGSOC: Limited Treatment Options with High Unmet Need



¹ NCCN guidelines

VERASTEM[®]

Therapy	Response Rate ORR	Median PFS Months (95% CI)	Discontinuation Rate due to AEs
Standard of Care ¹	6%	7.2 (5.6-9.9)	12 %
Trametinib ¹	26%	13.0 (9.9-15.0)	35%
Standard of Care ²	13%	10.6 (9.2 to 14.5)	17%
Binimetinib ²	16%	9.1 (7.3-11.3)	31%

¹ Gershenson, et al. ESMO 2019. ² Monk et al., | Clin Oncol 2020.

Standard of Care = letrozole, tamoxifen, chemotherapy PFS = Progression free survival *CI* = *confidence interval* 17



70% of LGSOC tumors driven by mutations in the RAS pathway

LGSOC is a type of ovarian cancer that disproportionately affects younger women


1,000 to 2,000 patients in the U.S. and 15,000 to 30,000 worldwide diagnosed with LGSOC each year

A slow growing cancer, that has a median survival of almost 10 years, so patients remain in treatment for a long time (10-yr prevalence ~80,000 worldwide, ~6,000 US)

Patients often experience significant pain and suffering from their disease over time

Most prior research has focused on high grade serous ovarian cancer (HGSOC). However, LGSOC is clinically, histologically and molecularly unique from HGSOC with limited treatments available

~30% of LGSOC Patients Have KRAS mt ~70% of LGSOC Shows RAS Pathway-Associated mts




References: AACR Project GENIE Cohort v9.0-public and Verastem unpublished analysis



Reference: Monk, Randall, Grisham, The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer, Am Soc Clin Oncol Educ Book; 2019; Slomovitz, Gourley, Carey, Malpica, Shih, Huntsman, Fader., Grisham et al, Low-Grade serous ovarian cancer: State of the Science; Gynecol Oncol; 2020. Grisham, Iyer, Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions; Curr Treat Options Oncology; 2018.

RAMP 201: KRAS Mutated (mt) and Wild Type (wt), Phase 2, Recurrent LGSOC Adaptive Design for Potential Accelerated Approval



FDA Was Supportive of Development Strategy, Adaptive Design, and Addition of KRAS wt to Selection Phase

Registration-directed Study Commenced in Nov. 2020 with estimated Primary Completion Date for the Expansion Phase of June 2023 (clinicaltrials.gov)




*Dosing: Defactinib + VS-6766 combo: Defactinib 200mg PO BID: 21/28 days + VS-6766 3.2mg PO 2x/wk 21/28 days; VS-6766 monotherapy: VS6766 4.0 mg PO 2x/wk 21/28 days **Expansion Phase – final sample size to be adjusted based on adaptive design

19


LGSOC market opportunity larger or comparable to other high unmet need KRAS opportunities

Prevalence



patients WW

Patient-months of Therapy Per Year² (across all 2L+ patients)






¹ References: Monk, Randall, Grisham, The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer, Am Soc Clin Oncol Educ Book; 2019; Slomovitz, Gourley, Carey, Malpica, Shih, Huntsman, Fader., Grisham et al, Low-Grade serous ovarian cancer: State of the Science; Gynecol Oncol; 2020. Grisham, Iyer, Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions; Curr Treat Options Oncology; 2018; Globocan 2020
² Patient-months of Therapy metric calculated by multiplying relevant incidence/prevalence rate times estimated duration of therapy; represents US market opportunity only; patient population estimates from Globocan 2020, American Cancer Society 2021, AACR Genie Cohort V9.0 public, and scientific publications. Duration of therapy estimates from clinical studies and clinician experience. Patient-months on therapy is for 2nd-line+ patients

³ NSCLC KRAS G12C 2nd line patients (incidence); Pancreatic RAS/RAF mutant 2nd-line patients (incidence); LGSOC KRAS mutant and wild-type patients (prevalence); Endometrioid RAS/RAF mutant 2nd-line patients (incidence); Uveal melanoma RAS/RAF mutant 2nd-line patients (incidence) 20


VS-6766 +/- Defactinib in NSCLC

High Unmet Need in Refractory KRAS mt NSCLC Adenocarcinoma



⁴ www.thelancet.com Vol 389 January 21, 2017


⁵ Adapted from NCCN Non-small cell lung cancer guidelines Version 3.2020



- SOC in recurrent disease is chemotherapy
- Pre-PD-(L)I era, chemotherapy response rate ~10% in recurrent disease; 12w PFS of 30–45%


VS-6766 Inhibits CRAF - The key driver of KRAS GI2V mt NSCLC

A Precision Approach to KRAS G12V Driven NSCLC




- KRAS G12V signals mainly through RAF/MEK in contrast to other variants, such as KRAS-G12D, which signal more through PI3K/AKT
- KRAS G12V models are especially dependent on CRAF


VERASTEM ONCOLOGY



CRAF Drives KRAS G12V mt NSCLC¹




BRAF KO Has No Effect



CRAF, but not BRAF, ablation improves survival of mice with KRAS GI2V induced lung cancer in vivo

References: Ishii et al. Cancer Res (2013), Blasco, R. B. et al. Cancer Cell (2011), Lito, P. et al. Cancer Cell (2014), Sanclemente, M. et al. Cancer Cell (2018)

VS-6766 +/- FAKi induces significant tumor regression in KRAS GI2V mt NSCLC in vivo model, with clear differentiation from trametinib



٠

٠

Case Study: Response to VS-6766 + defactinib in a patient with KRAS G12V mutant NSCLC VS-6766 + Defactinib

May 2019: Diagnosed with NSCLC

June 2019 - Sept 2019: Treated with first line Carboplatin + Pemetrexed + Pembrolizumab

Oct 2019: Progression, palliative RT to right hip

Nov 2019 – present: On treatment in FRAME study VS-6766 + Defactinib

Pre-treatment Oct 2019








On-treatment Feb 2021



Strong Signal Identified in KRAS GI2V NSCLC to Be Further Validated

VS-6766 ± Defactinib Has a Confirmed 57% ORR in KRAS G12V mt NSCLC in Integrated Analysis




- Preclinical evidence suggests combination with Defactinib may improve efficacy in KRAS GI2V mt NSCLC
- Activity of VS-6766 as a single agent and in combo with Defactinib in KRAS GI2V mt NSCLC



References: ¹ Guo, et al Lancet Oncology 2020 ² Krebs, AACR April 2021 (March 18, 2021 cutoff)

NSCLC Clinical Strategy: KRAS Mutant (mt), Enriched GI2V, Phase 2, Recurrent NSCLC for Potential Accelerated Approval (RAMP 202)



This Registration-directed Phase 2 Study commenced December 2020 with an estimated Primary Completion Date for the Expansion Phase of March 2023 (clinicaltrials.gov)

VERASTEM[®] ONCOLOGY

References:¹ Defactinib 200 mg PO BID (21/28 days) + VS-6766 3.2 mg PO 2x/wk (21/28 days)

Preclinical synergy of VS-6766 + GI2C inhibitors in KRAS GI2C mt models

2000-

1500

1000


500

SEM) volume

Tumor vc (mm³ +/-

Synergy of VS-6766 + G12C inhibitor AMG 510 across GI2C mutant NSCLC, CRC & Pancreatic cancer cell lines

			Combined Synergy Score	
Cell line	Indication	Sensitivity to G12C inhibitors	VS-6766 + AMG 510	VS-6766 + MRTX849
H2122	NSCLC	Moderately sensitive	44.7	44.6
H1373	NSCLC	Sensitive	10.0	3.4
SW1573	NSCLC	Insensitive	8.6	12.0
H358	NSCLC	Sensitive	6.9	5.4
H2030	NSCLC	Moderately sensitive	5.1	ND
SW837	CRC	Sensitive	16.1	18.5
MIAPACA2	Panc	Sensitive	2.3	5.3



VS-6766 & FAKi potentiate AMG 510 efficacy in KRAS G12C mutant NSCLC in vivo; Tumor regression in all mice with triple combination

Vehicle

VS-6766

AMG510

AMG510 + FAKi

AMG510 + VS-6766

AMG510 + VS-6766 + FAKi

Doses Tested

Trametinib: 0.3 mg/kg QD

VS-6766: 0.3 mg/kg QD


FAKi: 50 mg/kg BID AMG 510: 30 mg/kg QD

Reference: Coma et al., AACR 2021

ONCOLOGY

Acquired resistance mechanisms to KRAS GI2Ci treatment in patients further support combination of KRAS GI2Ci with VS-6766


Summary of Putative Mechanisms of Acquired Resistance to Adagrasib Treatment



- Mechanisms of acquired resistance to KRAS GI2Ci adagrasib treatment in patients recently reported^{1,2}
- The main resistance alterations occurred in
 - RTK mts or amplifications
 - KRAS mts or amplification
 - NRAS mt
 - BRAFV600E mt, BRAF or CRAF fusions
 - MAP2K1 (MEK1) mt/deletion
- VS-6766 is expected to be effective against these KRAS, NRAS, BRAF and CRAF modifications

We have initiated a clinical collaboration with Amgen to explore the combination of VS-6766 + sotorasib in NSCLC KRAS GI2C mt patients (RAMP 203)

- Patients must have known GI2C KRAS mutation determined using validated test
- Treatment with at least 1 but no more than 3 prior systemic regimens, for Stage 3B-C or 4 NSCLC
- Patient may have previously received adjuvant chemotherapy for earlier-stage disease
- Measurable disease according to RECIST 1.1
- ECOG performance status ≤ I




Part A (Dose Evaluation) portion of study expected to be initiated in 4Q 2021



Future Opportunities: VS-6766 as Backbone of RAS Therapy

Vertical Blockade: Preclinical synergy in combination with several promising targets VS-6766 + SOSIi (BI-3406)

100% (6/6)



ONCOLOGY


VS-6766 + pan-HERi (Afatinib) 100% (5/5)

40


-20


Combined Synergy Score

Indication



VS-6766 + G12Ci (AMG 510)





G12D

G12C

Combined Synergy Score

Indication

H2122 SW837 SW1573 H358

KRAS KRAS KRAS G12C G12D G12V VS-6766 + G12Ci (MRTX849)

40

Combined Synergy Score

VS-6766 + ERK1/2i (LY3214996)


AFIL

100% (5/5) 60% (3/5)

83% (5/6)


KRAS


G12V



Reference: Coma et al., AACR 2021

Parallel Pathway Inhibition: Two synergistic combinations already progressed to clinical stage VS-6766 + p70S6K/AKTi (M2698) VS-6766 + mTORi (Everolimus)





, E 2 2 2 5 5 5 5

KRAS

G12D

KRAS

G12V


KRAS

G12C

-10-

-20

Indication



G12C

G12D

G12V




Reference: Coma et al., RAS-Targeted Drug Discovery, Feb 2021

33

Corporate

KeyVSTM Milestones 2020-2022



Key Financial Statistics

As of September 30, 2021


Cash, cash equivalents & investments	\$103.4M
Shares fully diluted	I 96.9M
Insider ownership (outstanding / vested)	8.1% / 5.1%

* The 2018 Notes have an initial conversion rate of 139.5771 shares of Common Stock per \$1,000 which translates to an initial conversion price of \$7.16 per share of Common Stock.



Backup Slides

High Unmet Needs in RAS/RAF/MEK/ERK-Driven Cancers



Breadth of potential opportunity

 30% of all human cancers are driven by mutations of the RAS family of genes⁶

'ERASTEM

ONCOLOGY

Established prognostic significance

• Patients with mutations of the RAS family have an overall worse prognosis

Challenges with conventional approaches

- Modest progress; limited number of approved therapies
- Single agent therapies (e.g., MEK inhibitors) associated with resistance
- Tolerable combination regimens with MEK inhibitors have been challenging
- Current RAS inhibitors in development address only a minority of all RAS mutated cancers




¹Reference for RAS mt frequencies – Cox et al. *Nature Reviews* 13: 828, 2014; ²Reference for BRAF mt frequencies – Turski et al. *Mol Cancer Ther* 15: 533, 2016 ³85% of lung cancer is NSCLC (Lu et. al. *Cancer Manag Res.* 2019); ⁴90% of all uterine cancers are of the endometrial type (ACS); ⁵Cancer Statistics 2020, Siegel et. al. *CA Cancer J Clin* 2020;70:7-30; ⁶8 out of 10 thyroid cancers are of the papillary type (ACS) References:

McCormick F Clin Cancer Res 15April2015; ⁶Adderley H et al. EBioMedicine 01Mar2019; Papke B et al. Science 17Mar2017; Ryan M et al. *Nature Reviews Clinical Oncology* 01Oct2018; NIH cancer.gov/research/key-initiatives/ras

KRAS GI2V and GI2D Represent ~50% of KRAS Mutations across Human Cancers

% frequency in a total of 780 cancer patients with KRAS mutations¹




References:

¹ TCGA PanCancer Atlas (cBioPortal analysis)

² 90% of all uterine cancers are of the endometrial type (ACS)


³ Cancer Statistics 2020 (Siegel et al. CA Cancer J Clin 2020; 70:7-30)






VS-6766 and FAK inhibitor combination leads to more robust anti-tumor efficacy in vivo


KRAS^{mt} Ovarian TOV-21G in vivo Model¹







Overcoming Key Resistance Mechanisms to MEK Inhibitors



- MEK inhibition induces compensatory activation of pFAK preclinically and clinically
 - Trametinib induced ↑ pFAK (Y397) preclinically in KRAS mt NSCLC cell lines
 - Also observed in patients

 - Combination with defactinib reduced this compensatory pFAK signal

Pharmacokinetic Profiles of VS-6766 + Defactinib in Combination Similar to that seen in Single Agent Studies

Cohort	Dose (mg)	N	Subject	AUC _{0-24h} (h*ng/mL)	C _{max} (ng/mL)
	3.2	2	Mean	6179	354
1	(with 200mg VS)	3	CV%	32.1	30.4
2	4	F	Mean	5353	289
2a	(with 200mg VS)	5	CV%	15.8	16.0
2b	3.2 (with 400mg VS)	I	FRA101-007	3302	229

VS-6766


Defactinib

Cohort	Dose (mg)	N	Subject	AUClast (h*ng/mL)	Cmax (ng/mL)
200	200	3	Mean	2071	273
I	(with 3.2mg RO)		CV%	103	80
		5	Mean	2252	318
	200 (with 4mg RO)		CV%	124	117
400 2b (with 3.2mg RO)		Mean	2807	360	
		3	CV%	31	32




NSCLC Responses with VS-6766 + Defactinib Combination (n=20) Confirmed responses in 2/2 patients with KRAS GI2V mt NSCLC Tumor reduction in 4/6 patients with KRAS GI2C mt NSCLC

Best response by RECIST in KRAS mt NSCLC



Time on Treatment

Target exposure for preclinical tumor regression is covered by twice weekly dosing of 4 mgVS-6766 3 wks on/1 wk off



• Modeling of PK for 4 mgVS-6766 2/wk, 3 wks on/1 wk off, based on 4 mg single dose PK data (study NO21895)


• Relationship to average exposure for tumor regression in KRAS G12V mt NSCLC mouse model

VERASTEM

ONCOLOG


Status: Combination of VS-6766 with Everolimus (mTOR inhibitor)

- Synergy of VS-6766 + everolimus observed broadly across cancer cell lines with various KRAS mutation variants
- A well-tolerated RP2D for VS-6766 + everolimus has been established with intermittent dosing of both agents (twice weekly; 3 wks on/1 wk off)
- KRAS mutant NSCLC expansion cohort is currently ongoing with VS-6766 + everolimus





Combination of VS-6766 with anti-EGFR mAb induces tumor regression in a KRAS mt Colorectal PDX model




- VS-6766 + anti-EGFR (panitumumab) induces tumor regression in a KRAS G12V mt CRC patient-derived xenograft model
- G12Ci + anti-EGFR (sotorasib + panitumumab and adagrasib + cetuximab) have shown partial responses in KRAS G12C mt CRC (Fakih et al. ESMO 2021; Weiss et al. ESMO 2021)
- These data support clinical testing of VS-6766 + anti-EGFR for treatment of KRAS mt CRC




Collaboration with Marwan Fakih, City of Hope


VS-6766 monotherapy has shown clinical activity in several cancer indications, including NSCLC







VS-6766 upregulates MHC Class I antigens on tumor cells: a mechanism for potentiation of I/O efficacy





TAP-1






Cell Line	Tumor type	RAS/RAF mutation status	
A549	Lung	KRASmt G12S	
TOV21g	Ovarian	KRASmt GI3C	
SKMEL5	Melanoma	BRAFmt V600E	
IGR-I	Melanoma	BRAFmtV600E	
WMI15	Melanoma	BRAFmt V600E	


VS-6766 @ I μ M (except SKMEL5 and IGR-I, 300 nM)

VERASTEM[®]

VS-6766 enhances tumor growth inhibition when combined with anti-PD-I in the CT26 KRAS (GI2D) syngeneic model



LGSOC Market Opportunity – Reference Calculations



¹ Prevalence used for LGSOC patient population estimate. References: Monk, Randall, Grisham, The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer, Am Soc Clin Oncol Educ Book; 2019; Slomovitz, Gourley, Carey, Malpica, Shih, Huntsman, Fader., Grisham et al, Low-Grade serous ovarian cancer: State of the Science; Gynecol Oncol; 2020. Grisham, Iyer, Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions; Curr Treat Options Oncology; 2018; Globocan 2020

² Patient-months of Therapy metric calculated by multiplying relevant incidence/prevalence rate times estimated duration of therapy; represents US market opportunity only; patient population estimates from Globocan 2020, American Cancer Society 2021, AACR Genie Cohort 9.0 public, and scientific publications. Duration of therapy estimates from clinical studies and clinician experience. Number of patients and months on therapy are for 2nd-line+

³ NSCLC KRAS G12C 2nd line patients (incidence); Pancreatic RAS/RAF mutant 2nd-line patients (incidence); Endometrioid RAS/RAF mutant 2nd-line patients (incidence); Uveal melanoma RAS/RAF mutant 2nd-line patients (incidence)



A drug with a Breakthrough designation will have⁽¹⁾...

- Increased communication with FDA during drug development and review
- FDA guidance to ensure that the design of clinical trials are as efficient as practicable
- A cross-disciplinary project lead assigned to the FDA review team and increased involvement of senior managers and experienced review staff
- Based on the criteria for the grant of breakthrough designation, may represent substantial improvement over existing clinical therapies



List of Oncology Drugs that Received Breakthrough Therapy Designation

Sr no.	Proprietary Name	Established Name	Current Approval Status	Company
1.	Zykadia	Ceritinib	Approved	Novartis
2.	Ibrance	Palbociclib	Approved	Pfizer
3.	Keytruda	Pembrolizumab	Approved	Merck
4.	Opdivo	Nivolumab	Approved	Bristol Myers Squibb
5.	Tagrisso	Osimertinib	Approved	Lilly
6.	Alecensa	Alectinib	Accelerated Approval	Genentech
7.	Xalkori	Crizotinib	Approved	Pfizer
8.	Lenvima	Lenvatinib	Approved	Eisai
9.	Tecentriq	Atezolizumab	Approved	Genentech
10.	Rubraca	Rucaparib	Approved	Clovis Oncology
11.	Kisqali	Ribociclib	Approved	Novartis
12.	Zejula	Niraparib	Approved	GSK
13.	Alunbrig	Brigatinib	Accelerated Approval	Takeda
14.	Kisqali Femara Co-Pack	Letrozole & Ribociclib	Approved	Novartis
15.	Tafinlar	Dabrafenib	Approved	Novartis
16.	Mekinist	Trametinib	Approved	Novartis
17.	Verzinio	Abemaciclib	Approved	Lilly
18.	Imfinzi	Durvalumab	Approved	AstraZeneca
19.	Yervoy	Ipilimumab	Approved	Bristol Myers Squibb
20.	Azedra	lobenguane	Approved	Progenics Pharmaceuticals
21.	Lorbrena	Lorlatinib	Approved	Pfizer
22.	Kadcyla	Ado-trastuzumab emtansine	Approved	Genentech
23.	Padcev	Enfortumab vedotin-ejfv	Approved	Astellas Pharma
24.	Enhertu	Fam-trastuzumab deruxtecan- nxki	Approved	Daiichi-Sankyo
25.	Jelmyto	Mitomycin	Approved	UroGen Pharma
26.	Tukysa	Tucatinib	Approved	Seagen
27.	Trodelvy	Sacituzumab Govitecan-hziy	Approved	Gilead
28.	Tabrecta	Capmatinib	Approved	Novartis
29.	Retevmo	Selpercatinib	Approved	Lilly
30.	Gavreto	Pralsetinib	Approved	Blueprint medicines
31.	N/A	VS6766/Defactinib	Not yet approved	Verastem
32.	Lumakras	Sotorasib	Accelerated Approval	Amgen
33.	N/A	177Lu-PSMA-617	Not yet approved	Novartis
34.	Ayvakit	Avapritinib	Approved (Mast Cell Leukemia)	Blueprint Medicines Corp
35.	N/A	Adagrasib	Not yet approved (NSCLC)	Mirati Therapeutics, Inc.



Strong Patent Protection

- COM for VS-6766 to 2027 & defactinib to 2028, Hatch Waxman should extend to 2032
- VS-6766 intermittent dosing regimen until 2038 if granted
- FAK/MEK combination to 2035
- VS-6766/defactinib combination until 2040 if granted
- Method of manufacture for VS-6766 to 2032
- Other activity related to patent protection is ongoing and will continue into the future



Experienced Senior Management Team



Brian Stuglik Chief Executive Officer

- Global VP & Chief Marketing Officer – Lilly Oncology
- Founding Member Proventus Health Solutions



Daniel Paterson President and Chief Operating Officer

- CEO The DNA Repair Co. (now On-Q-ity)
- PharMetrics (now IMS), Axion



Rob Gagnon Chief Business and Financial Officer

- CFO Harvard Bioscience, Clean Harbors
- VP of Finance Biogen Idec



Cathy Carew Chief Organizational Effectiveness Officer

- Principal HR Collaborative
- Ironwood, ActiveBiotics, Dynogen, Tufts Health Plan



Hagop Youssoufian, MSc, M.D.

- Head of Medical Strategy
- CMO, BIND Therapeutics, EVP, Progenics,
- CMO & EVP, Ziopharm Oncology, SVP, Imclone





Jonathan Pachter, Ph.D. Chief Scientific Officer

- Head of Cancer Biology OSI (now Astellas)
- Schering-Plough



Louis Denis, M.D. Chief Medical Officer

- CMO, Asana BioSciences
- Boehringer-Ingelheim, Pfizer



THANK YOU